146 results on '"Neumann, Uta"'
Search Results
2. Satisfaction with a new patient education program for children, adolescents, and young adults with differences of sex development (DSD) and their parents.
3. Who is sensitising whom? A participatory interview guide development as an awareness tool within a health care research project
4. Development and evaluation of a patient education programme for children, adolescents, and young adults with differences of sex development (DSD) and their parents: study protocol of Empower-DSD
5. Self- and proxy-reported outcomes after surgery in people with disorders/differences of sex development (DSD) in Europe (dsd-LIFE)
6. Webinars for patient education on congenital adrenal hyperplasia
7. Temporal Trends in Acute Adrenal Insufficiency Events in Children With Congenital Adrenal Hyperplasia During 2019-2022
8. Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia Patients
9. Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
10. Intersexual Twins due to Tetragametic Chimerism
11. The genetic diagnosis of rare endocrine disorders of sex development and maturation: a survey among Endo-ERN centres
12. Das Marktphasenschema: Operationalisierung wesentlicher Aussagen
13. Abschließende Beurteilung
14. Das Marktphasenschema: Empirische Überprüfung am Markt für Elektrische Haushaltsgeräte
15. Theoretische Grundlagen
16. Blood pressure (BP) status in Congenital Adrenal Hyperplasia (CAH) – longitudinal analysis of real world data from the I-CAH registry
17. Primary sulphonylurea therapy in a newborn with transient neonatal diabetes attributable to a paternal uniparental disomy 6q24 (UPD6)
18. Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency
19. Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
20. Treatment of congenital adrenal hyperplasia in children aged 0–3 years: a retrospective\ud multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure
21. Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe
22. The genetic diagnosis of rare endocrine disorders of sex development and maturation:a survey among Endo-ERN centres
23. Treatment of congenital adrenal hyperplasia in children aged 0–3 years:A retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure
24. Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
25. Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
26. The genetic diagnosis of rare endocrine disorders of sex development and maturation: a survey among Endo-ERN centres
27. Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe
28. Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis
29. Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients
30. International practice of therapy monitoring in congenital adrenal hyperplasia - Real World data from the I-CAH registry
31. Variation of glucocorticoid dose and biomarkers in children with congenital adrenal hyperplasia longitudinal analysis of real world data from the I-CAH registry
32. Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
33. Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling
34. Real world estimates of adrenal insufficiency related adverse events in children with congenital adrenal hyperplasia
35. Physical and Reported Subjective Health Status in 222 Individuals with XY Disorder of Sex Development
36. Self- and proxy-reported outcomes after surgery in people with disorders/differences of sex development (DSD) in Europe (dsd-LIFE)
37. Problemstellung und Zielsetzung
38. Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling
39. Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21-hydroxylase deficiency in Europe
40. International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia:Data from the I-CAH registry
41. International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: Data from the I-CAH registry
42. Real-World Estimates of Adrenal Insufficiency-Related Adverse Events in Children with Congenital Adrenal Hyperplasia
43. Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21‑hydroxylase deficiency in Europe
44. Rationale for a reduced dexamethasone dosis in prenatal CAH therapy based on pharmacokinetic modelling
45. International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry
46. Diagnosis of DSD in Children—Development of New Tools for a Structured Diagnostic and Information Management Program within the Empower-DSD Study.
47. Response to ‘Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia’
48. Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children
49. Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal Hyperplasia
50. A Prospective Study of Children Aged 0–8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.